Publications

Drug metabolism and disposition: the biological fate of chemicals

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

01-01-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

15-12-2008

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

01-06-2008

Drug metabolism and disposition: the biological fate of chemicals

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

01-04-2008

Molecular pharmacology

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

01-03-2008

Antimicrobial agents and chemotherapy

P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

01-03-2008

Molecular cancer therapeutics

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

01-12-2007

The Journal of clinical investigation

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

01-11-2007

American journal of physiology. Cell physiology

Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.

01-06-2007

Molecular and cellular biology

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

01-02-2007

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

New physiological functions for drug-transporting P-glycoproteins?

10-11-2006

Clinical cancer research : an official journal of the American Association for Cancer Research

Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.

15-10-2006

The Journal of pharmacology and experimental therapeutics

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

01-07-2006

Carcinogenesis

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

01-01-2006

Trends in pharmacological sciences

The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

01-01-2006

Cancer chemotherapy and pharmacology

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

01-10-2005

International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005

Stem cells (Dayton, Ohio)

Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice.

01-09-2005

Drug metabolism and disposition: the biological fate of chemicals

Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.

01-07-2005

Drug metabolism and disposition: the biological fate of chemicals

Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).

01-05-2005

Molecular pharmacology

Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.

01-05-2005

Molecular pharmacology

The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.

01-05-2005

Cancer research

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

01-04-2005

Nature medicine

The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.

01-02-2005

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

The Journal of pharmacology and experimental therapeutics

Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).

01-01-2004

Molecular and cellular biology

Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.

01-11-2003

Cancer research

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

01-10-2003

The Journal of biological chemistry

Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).

27-06-2003

Cancer research

Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.

15-03-2003

The Journal of pharmacology and experimental therapeutics

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

01-02-2003

Advanced drug delivery reviews

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

21-01-2003

Proceedings of the National Academy of Sciences of the United States of America

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

26-11-2002

AIDS (London, England)

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

22-11-2002

Pharmacogenetics

Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences?

01-11-2002

Molecular cancer therapeutics

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

01-04-2002

Advances in experimental medicine and biology

The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers.

05-01-2002

Genes & development

Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes.

15-09-2001

Cancer research

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

15-04-2001

Molecular pharmacology

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

01-04-2001

Annals of the New York Academy of Sciences

Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.

24-02-2001

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

01-12-2000

Journal of the National Cancer Institute

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

18-10-2000

Cancer research

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

15-10-2000

The Journal of clinical investigation

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

01-02-2000

The Journal of clinical investigation

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

01-11-1999

Cancer research

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

01-09-1999

British journal of pharmacology

Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.

01-05-1999

Advanced drug delivery reviews

P-Glycoprotein, a gatekeeper in the blood-brain barrier.

05-04-1999

The Journal of pharmacology and experimental therapeutics

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

01-04-1999